Table 1.
Baseline Demographics of Patients Who Achieved a Complete Response, Partial Response, or Hematological Improvement with Azacitidine (n = 91)
| Characteristic | No. of Patients (%) |
|---|---|
| Sex | |
| Male | 71 (78) |
| Female | 20 (22) |
| French-American-British classification | |
| Refractory anemia with excess blasts | 60 (66) |
| Refractory anemia with excess blasts in transformation | 24 (26) |
| Chronic myelomonocytic leukemia | 4 (4) |
| Not per protocola | 2 (2) |
| Indeterminate | 1 (1) |
| Eastern Cooperative Oncology Group performance status score | |
| 0 | 47 (52) |
| 1 | 39 (43) |
| 2 | 4 (4) |
| Missing | 1 (1) |
| Duration of myelodysplastic syndromes, y | |
| Mean ± standard deviation | 1.2 ±2.0 |
| Median (range) | 0 (0−10) |
| Number of cytopenias | |
| 1 | 3 (3) |
| 2 | 30 (33) |
| 3 | 58 (64) |
| International Prognostic Scoring System | |
| Intermediate-1 risk | 3 (3) |
| Intermediate-2 risk | 38 (42) |
| High risk | 44 (48) |
| Not applicablea | 2 (2) |
| Indeterminate | 4 (4) |
| International Prognostic Scoring System cytogenetics | |
| Good | 43 (47) |
| Intermediate | 17 (19) |
| Poor | 26 (29) |
| Missing | 5 (6) |
| Red blood cell transfusion dependence | 57 (63) |
a
Includes 1 patient with acute myelogenous leukemia and 1 patient with myeloproliferative disease.